Charles River expands early discovery services

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/JK1991)
(Image: Getty/JK1991)
Charles River has upped to its early discovery capabilities with the addition of high-throughput technologies and expanded pharmacokinetic services.

According to Charles River, it is the first contract research organization (CRO) to provide clients access to Apricot Designs' Dual Arm (ADDA) system in North America and Europe.

Designed for drug discovery, the system is a high-speed autosampler for liquid chromatography/mass spectrometry (LC/MS).

“Apricot Designs’ dual arm autosampler was designed with early discovery scientists in mind,” ​said Felix H. Yiu, founder and CEO, Apricot Designs, Inc. in a press release. “It enables seamless integration with LC/MS systems, accelerating the laboratory research process and yielding the best results.”

Charles River has also geographically expanded its pharmacokinetic (PK) capabilities in San Francisco and 's-Hertogenbosch, The Netherlands.

“The early discovery industry is seeing a marked shift towards a better understanding of the underlying biology of candidate compounds. Both HT-ADME and PK technologies are critical to that understanding, and to developing more successful candidates in early discovery,”​ explained Ian Waddell, PhD, executive director, biology, Charles River.

Related news

Show more

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us


View more